Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Triple Negative Breast Neoplasms 1Recurrence 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Ovarian Cancer Recurrent 1Neoplasm Metastasis 1Hematologic Neoplasms 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Carboplatin 23Paclitaxel 14pembrolizumab 8liposomal doxorubicin 7Bevacizumab 5Specimen Handling 4Cyclophosphamide 4olaparib 3niraparib 3epacadostat 3Topotecan 3Taxes 3Nivolumab 3Magnetic Resonance Spectroscopy 3Gemcitabine 3Biopsy 3sarilumab 2rucaparib 2poly ICLC 2durvalumab 2cemiplimab 2STA 9090 2Injections 2Immunoglobulin G 2Drug Therapy 2Docetaxel 2Disulfides 2Cisplatin 2veliparib 1tremelimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Fallopian Tube Neoplasms × poly(I).poly(c12,U) × Clear all
NCT01312389 2021-11-15

A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Abramson Cancer Center at Penn Medicine

Phase 1/2 Terminated
3 enrolled 4 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡